Stay updated on Safety and Efficacy of Ibrutinib and Pembrolizumab in CLL/MCL Clinical Trial

Sign up to get notified when there's something new on the Safety and Efficacy of Ibrutinib and Pembrolizumab in CLL/MCL Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Safety and Efficacy of Ibrutinib and Pembrolizumab in CLL/MCL Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    The page’s displayed revision/version number was updated from v3.5.2 to v3.5.3. This reflects a tooling/version update without indicating changes to the study details.
    Difference
    0.1%
    Check dated 2026-04-24T06:08:24.000Z thumbnail image
  2. Check
    9 days ago
    Change Detected
    Summary
    Revision updated from v3.5.0 to v3.5.2.
    Difference
    0.1%
    Check dated 2026-04-17T02:43:27.000Z thumbnail image
  3. Check
    16 days ago
    No Change Detected
  4. Check
    24 days ago
    Change Detected
    Summary
    Added 'B-cell chronic lymphocytic leukemia' as a disease keyword on the Study Details page.
    Difference
    0.1%
    Check dated 2026-04-02T15:37:29.000Z thumbnail image
  5. Check
    38 days ago
    Change Detected
    Summary
    Revision tag updated to v3.5.0, replacing the previous v3.4.3. No visible changes to study details or page layout.
    Difference
    0.1%
    Check dated 2026-03-19T06:00:37.000Z thumbnail image
  6. Check
    45 days ago
    Change Detected
    Summary
    Footer revision label updated from v3.4.2 to v3.4.3.
    Difference
    0.1%
    Check dated 2026-03-12T02:37:40.000Z thumbnail image
  7. Check
    59 days ago
    Change Detected
    Summary
    - No visible content changes between the two screenshots. The page content and structure appear identical.
    Difference
    0.1%
    Check dated 2026-02-25T21:51:09.000Z thumbnail image

Stay in the know with updates to Safety and Efficacy of Ibrutinib and Pembrolizumab in CLL/MCL Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Safety and Efficacy of Ibrutinib and Pembrolizumab in CLL/MCL Clinical Trial page.